[go: up one dir, main page]

AR037611A1 - Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden - Google Patents

Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden

Info

Publication number
AR037611A1
AR037611A1 ARP020104638A ARP020104638A AR037611A1 AR 037611 A1 AR037611 A1 AR 037611A1 AR P020104638 A ARP020104638 A AR P020104638A AR P020104638 A ARP020104638 A AR P020104638A AR 037611 A1 AR037611 A1 AR 037611A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
halogen
heterocyclyl
heteroaryl
Prior art date
Application number
ARP020104638A
Other languages
English (en)
Inventor
Ann Marie Madera
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR037611A1 publication Critical patent/AR037611A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuesto derivados de amino-tetralina de fórmula general (1), en la cual: R1 es alquilo C1-6; R2 es halógeno u -OR'; R3 es hidrógeno u -OR'; R' es hidrógeno, alquilo C1-6, o -SO2R''; R'' es alquilo C1-6, halogenoalquilo C1-6, arilo o heteroarilo, donde dichos grupos arilo o heteroarilo son opcionalmente sustituidos por un grupo seleccionado entre alquilo C1-6, halógeno, halogenoalquilo C1-6, ciano, nitro, alquilsulfonilo C1-6 y alquilsulfonilamino C1-6; R4 es alquilo C1-6, arilo, heterociclilo o heteroarilo, donde dichos grupos arilo, heterociclilo o heteroarilo son opcionalmente sustituidos por uno o dos grupos seleccionados entre el grupo que consiste en alquilo C1-6, halógeno, halogeno-alquilo C1-6, alcoxi C1-6, ciano, amino, mono- o di-alquilamino C1-6, nitro, alquilsulfonilo C1-6, alquilcarbonilo C1-6, urea, alquilcarbonilamino C1-6, alquilsulfonilamino C1-6, alquilaminosulfonilo C1-6, alcoxicarbonilo C1-6, heterociclilo y heteroarilo, o -NR5R6; y R5 y R6 son, independientemente entre sí, hidrógeno, alquilo C1-6, arilo o heterociclilo; donde dichos grupos arilo o heterociclilo son opcionalmente sustituidos por alquilo C1-6, halógeno, halogeno-alquilo C1-6, ciano, alcoxi C1-6 o alquilsulfonilo C1-6; o isómeros individuales, una mezcla racémica o no racémica de isómeros, o sales o solvatos farmacéuticamente aceptables de los mismos. Su uso, un procedimiento para su preparación y composiciones farmacéuticas que los comprenden. Los compuestos de fórmula (1) son útiles como agentes terapéuticos. En forma general son antagonistas de los receptores M2/M3 muscarínicos por lo que son particularmente útiles en el tratamiento de estados de enfermedad asociados con una función impropia de los músculos lisos y trastornos respiratorios.
ARP020104638A 2001-12-03 2002-12-02 Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden AR037611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33667501P 2001-12-03 2001-12-03

Publications (1)

Publication Number Publication Date
AR037611A1 true AR037611A1 (es) 2004-11-17

Family

ID=23317154

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104638A AR037611A1 (es) 2001-12-03 2002-12-02 Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden

Country Status (16)

Country Link
US (2) US6635658B2 (es)
EP (1) EP1453806B1 (es)
JP (1) JP4322675B2 (es)
KR (1) KR100668231B1 (es)
CN (1) CN100358870C (es)
AR (1) AR037611A1 (es)
AT (1) ATE381541T1 (es)
AU (1) AU2002352124A1 (es)
BR (1) BR0214649A (es)
CA (1) CA2469055C (es)
DE (1) DE60224221T2 (es)
ES (1) ES2297029T3 (es)
MX (1) MXPA04005313A (es)
PL (1) PL370799A1 (es)
RU (1) RU2311408C2 (es)
WO (1) WO2003048125A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100358870C (zh) * 2001-12-03 2008-01-02 弗·哈夫曼-拉罗切有限公司 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070021487A1 (en) 2003-04-11 2007-01-25 Mohammad Salman Azabicyclo derivatives as muscarinic receptor antagonists
CA2573673A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1828174A1 (en) * 2004-11-19 2007-09-05 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
US9198897B2 (en) * 2005-01-19 2015-12-01 Neurohealing Pharmaceuticals, Inc. Methods and compositions for decreasing saliva production
AP2007004234A0 (en) 2005-04-22 2007-12-31 Alantos Pharm Holding Dipeptidyl peptidase-IV inhibitors
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
EP2379080A1 (en) 2009-01-13 2011-10-26 ProteoSys AG Pirenzepine as otoprotective agent
KR102151832B1 (ko) * 2012-11-20 2020-09-03 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충제 화합물 및 조성물 및 이의 사용 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
CA1331191C (en) 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
FR2659323B1 (fr) 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
FR2659853A1 (fr) 1990-03-22 1991-09-27 Midy Spa Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
HUP9904167A3 (en) * 1996-07-01 2000-07-28 Schering Corp 1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the same
DK0912515T3 (da) * 1996-07-10 2003-03-10 Schering Corp 1,4-Disubstituerede piperidiner som muscarinantagonister
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
WO2001090082A1 (en) 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
JP4071000B2 (ja) 2000-05-25 2008-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換１−アミノアルキルラクタム及びムスカリン受容体アンタゴニストとしてのそれらの使用
CN100358870C (zh) * 2001-12-03 2008-01-02 弗·哈夫曼-拉罗切有限公司 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物

Also Published As

Publication number Publication date
BR0214649A (pt) 2004-11-03
US6635658B2 (en) 2003-10-21
CA2469055A1 (en) 2003-06-12
PL370799A1 (en) 2005-05-30
AU2002352124A1 (en) 2003-06-17
DE60224221D1 (de) 2008-01-31
JP2005518368A (ja) 2005-06-23
CN1639124A (zh) 2005-07-13
ES2297029T3 (es) 2008-05-01
WO2003048125A1 (en) 2003-06-12
US6806278B2 (en) 2004-10-19
KR20050044641A (ko) 2005-05-12
KR100668231B1 (ko) 2007-01-16
CA2469055C (en) 2011-03-29
RU2004120558A (ru) 2005-07-20
EP1453806A1 (en) 2004-09-08
CN100358870C (zh) 2008-01-02
US20030171362A1 (en) 2003-09-11
ATE381541T1 (de) 2008-01-15
JP4322675B2 (ja) 2009-09-02
EP1453806B1 (en) 2007-12-19
DE60224221T2 (de) 2008-12-11
MXPA04005313A (es) 2004-09-13
RU2311408C2 (ru) 2007-11-27
US20040092604A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR054799A1 (es) Derivados de oxindol
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AR004972A1 (es) Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.
ECSP045073A (es) Nuevos derivados de piperazina
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
ES2179353T3 (es) Antagonistas muscarinicos.
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
ECSP056115A (es) ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR044662A1 (es) Compuestos de azetidina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal